Antisense Therapeutics Limited announced the transition of Non-Executive Director Charmaine Gittleson M.D to become the Chair of the ANP Board. As part of the transition, Bob Moses, ANP Chairman since 2001, has announced that he intends to retire from the Board at the conclusion of the Company's 2021 Annual General Meeting after which he will continue to support the Company in a consultant capacity. The transitioning of the Chair role is in recognition of the ANP's maturation from a drug discovery to late-stage clinical development group with near term commercialisation aspirations. The Board believes that Dr Gittleson's extensive international experience in global pharmaceutical drug development and registration across multiple therapeutic and rare disease areas, is precisely the leadership and experience required to steward the Company through this next phase of the Company's growth.